In summary, our data in primary neoplastic B-cells is consistent with findings by others that pevonedistat enhances the anti-tumor activity of TRAIL in solid tumor cell lines [56], thus suggesting that pevonedistat should be further investigated in therapy of CLL and NHL. This evidence concerns the gene TNFSF10 and B-cell chronic lymphocytic leukemia.